



Making Science work for you...

# Jubilant Organosys Ltd.

Regd.Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar - 244 223 (U.P.)

Q1 FY 2008

Net Sales up  
**31%**

EBIDTA up  
**147%**

PAT up  
**210%**

## Unaudited Financial Results for the Quarter ended 30th June, 2007

(Rs. in Million)

(Rs. in Million)

CONSOLIDATED RESULTS			Particulars	JUBILANT ORGANOSYS LTD.		
Quarter Ended June 30 (Unaudited)	Year Ended March 31 (Audited)	Quarter Ended June 30 (Unaudited)		Year Ended March 31 (Audited)		
2007	2006	2007		2006	2007	
2953	2659	11116	Domestic sales & services	2949	2659	11111
2789	1766	8318	International sales	1942	1241	6323
<b>5742</b>	<b>4425</b>	<b>19434</b>	<b>Gross sales</b>	<b>4891</b>	<b>3900</b>	<b>17434</b>
(342)	(313)	(1337)	Less: Excise duty on Sales	(342)	(313)	(1337)
<b>5400</b>	<b>4112</b>	<b>18097</b>	<b>Net sales</b>	<b>4549</b>	<b>3587</b>	<b>16097</b>
996	44	1234	Other income	905	41	968
<b>6396</b>	<b>4156</b>	<b>19331</b>	<b>Total income</b>	<b>5454</b>	<b>3628</b>	<b>17065</b>
<b>4448</b>	<b>3367</b>	<b>15560</b>	<b>Total expenditure</b>	<b>3595</b>	<b>2848</b>	<b>13402</b>
9	27	(249)	a) (Increase)/Decrease in stock of manufactured goods	(32)	(23)	(193)
126	90	392	b) Cost of trading goods sold	126	68	366
2298	1745	8160	c) Raw & process materials consumed	2187	1700	7916
312	228	1133	d) Stores, spares, chemicals, catalyst & packing material consumed	240	202	961
348	296	1305	e) Manufacturing expenses			
114	99	533	– Cost of power & fuel	338	296	1298
694	471	2149	– Other manufacturing expenses	108	96	512
547	411	2137	f) Staff cost	271	202	975
<b>1948</b>	<b>789</b>	<b>3771</b>	g) Selling, general & admin. expenses	357	307	1567
			<b>Operating profit before interest and depreciation</b>	<b>1859</b>	<b>780</b>	<b>3663</b>
84	55	195	Interest (Net)	63	40	151
194	146	623	Depreciation	141	124	516
<b>1670</b>	<b>588</b>	<b>2953</b>	<b>Profit before tax</b>	<b>1655</b>	<b>616</b>	<b>2996</b>
273	139	712	Provision for tax (including Deferred Tax & Fringe Benefits Tax and net of reversals)	271	142	681
<b>1397</b>	<b>449</b>	<b>2241</b>	<b>Net profit after tax</b>	<b>1384</b>	<b>474</b>	<b>2315</b>
(32)	(12)	(39)	Minority Interest	–	–	–
<b>1429</b>	<b>461</b>	<b>2280</b>	<b>Net profit after Minority Interest</b>	<b>1384</b>	<b>474</b>	<b>2315</b>
143.5	143.1	143.5	Paid-up share capital (Face value of the share is Re.1)	143.5	143.1	143.5
	–	8918	Reserves (excluding revaluation reserve)		–	9473
			Earnings per share (Not annualized)			
<b>9.96</b>	<b>3.22</b>	<b>15.93</b>	<b>Basic (Rs.)</b>	<b>9.65</b>	<b>3.32</b>	<b>16.17</b>
<b>8.02</b>	<b>2.77</b>	<b>13.02</b>	<b>Diluted (Rs.)</b>	<b>7.77</b>	<b>2.85</b>	<b>13.22</b>
			Aggregate of non-promoter shareholding			
69068780	68681002	69067310	– Number of shares (Re 1 each)	69068780	68681002	69067310
48.15	48.01	48.15	– Percentage of shareholding	48.15	48.01	48.15

### Notes:

- On 1st June, 2007, the company through its wholly owned subsidiaries has acquired 100% stake in Hollister -Stier Laboratories LLC (HSL), a US Based company engaged in Contract Manufacturing of sterile injectables & Producers of allergenic extracts. The Consolidated financial results of the quarter includes results of June, 2007 of HSL.
- On 23rd May, 2007, the company subscribed to 7,00,000 Equity shares of the face value of Rs 10/- each at a premium of Rs. 36.15 each in cash in First Trust Healthcare Limited (FTHC) to acquire 51.85% stake. The FTHC is engaged in the business of Development & Management of Hospitals & Health Care units and is run by a team of professional doctors in West Bengal.
- The company invested Rs. 208.50 million in Jubilant Infrastructure Ltd., a wholly owned subsidiary engaged in setting up of SEZs in the states of Gujarat and Karnataka.
- During the Quarter, under the Jubilant Employee Stock Option Plan 2005, 1470 Shares were allotted on exercise of 294 vested options.
- Other Income includes exchange gain of Rs. 879 million on foreign currency borrowings including Foreign Currency Convertible Bonds (previous year Q1 FY 2007, exchange loss of Rs. 46 million and for FY 2007, exchange gain of 658 million).
- Performance Polymers Segment has been combined with Industrial Products Segment as in the opinion of the management the same is more representative in the current circumstances.
- Figures for previous period / year have been regrouped / reclassified / restated, wherever considered necessary.
- Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New - 43, Disposals - 43, Closing Balance - Nil.
- The above un-audited results which were subjected to limited review by the auditors of the company, were reviewed by the Audit Committee and were taken on record by the Board of Directors at its meeting held on 17th July, 2007.

For Jubilant Organosys Ltd.

Place : Noida

Dated : 17th July, 2007

Shyam S Bhartia  
Chairman & Managing Director

visit us at [www.jubl.com](http://www.jubl.com)

Segment Wise Revenue, Results & Capital Employed (Under Clause 41 of the Listing Agreement)						
CONSOLIDATED RESULTS			Particulars	JUBILANT ORGANOSYS LTD.		
Quarter Ended June 30 (Unaudited)	Year Ended March 31 (Audited)	Quarter Ended June 30 (Unaudited)		Year Ended March 31 (Audited)		
2007	2006	2007		2006	2007	
3194	2129	9523	<b>Segment revenue</b>			
			a. Pharmaceuticals and Life Science Products & Services	2347	1595	
2564	2316	9988	b. Industrial & Performance Products	2560	2325	
<b>5758</b>	<b>4445</b>	<b>19511</b>	<b>Gross sales</b>	<b>4907</b>	<b>3920</b>	
16	20	77	Less : Inter segment revenue	16	20	
342	313	1337	Less : Excise duty on Sales	342	313	
<b>5400</b>	<b>4112</b>	<b>18097</b>	<b>Net sales</b>	<b>4549</b>	<b>3587</b>	
3113	2060	9226	a. Pharmaceuticals and Life Science Products & Services	2266	1526	
2287	2052	8871	b. Industrial & Performance Products	2283	2061	
<b>5400</b>	<b>4112</b>	<b>18097</b>	<b>Total</b>	<b>4549</b>	<b>3587</b>	
			<b>Segment results (profit(+)/ loss(-) before tax and interest from each segment)</b>			
646	396	1797	a. Pharmaceuticals and Life Science Products & Services	697	409	
331	260	1033	b. Industrial & Performance Products	331	260	
<b>977</b>	<b>656</b>	<b>2830</b>	<b>Total</b>	<b>1028</b>	<b>669</b>	
84	55	195	Less : i. Interest	63	40	
(777)	13	(318)	ii. Other un-allocable expenditure (net of un-allocable income)	(690)	13	
<b>1670</b>	<b>588</b>	<b>2953</b>	<b>Total profit before tax</b>	<b>1655</b>	<b>616</b>	
			<b>Capital Employed (Segment assets less Segment liabilities)</b>			
20876	11769	14115	a. Pharmaceuticals & Life Science Products & Services	9814	7754	
5747	5104	5499	b. Industrial & Performance Products	5745	5095	
<b>26623</b>	<b>16873</b>	<b>19614</b>	<b>Total Capital employed in segments</b>	<b>15559</b>	<b>12849</b>	
2483	9706	7508	Add: Un-allocable corporate assets less liabilities	12543	12486	
<b>29106</b>	<b>26579</b>	<b>27122</b>	<b>Total capital employed in the Company</b>	<b>28102</b>	<b>25335</b>	